Rituxan

(Rituximab)

ApprovedMonoclonal antibody

Rituximab is used to treat certain cancers (like lymphoma and leukemia) and autoimmune diseases (like rheumatoid arthritis) by targeting and destroying specific immune cells that are either cancerous or causing harmful inflammation.[2] Rituxan is currently approved and in use across 177 indications[4].[1]

Rituxan is one of 1689 biologic programs targeting Pompe Disease. It is currently in Approved.

177

Indications

1,845

Total Trials

Active Trials

1,688

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Pompe DiseaseCompleted

Aplastic AnemiaRecruiting

Myasthenia GravisCompleted

Multiple MyelomaCompleted

Chronic Graft Versus Host DiseaseRecruiting

Systemic Lupus ErythematosusTerminated

Rheumatoid ArthritisRecruiting

Follicular LymphomaUnknown status

Hairy Cell LeukemiaCompleted

Idiopathic Pulmonary FibrosisCompleted

Pompe DiseaseApproved

Completed

Aplastic AnemiaPhase 2

Recruiting

Myasthenia GravisPhase 3

Completed

Multiple MyelomaPhase 2

Completed

Chronic Graft Versus Host DiseasePhase 2

Recruiting

Systemic Lupus ErythematosusPhase 3

Terminated

Rheumatoid ArthritisApproved

Recruiting

Follicular LymphomaPhase 3

Unknown status

Hairy Cell LeukemiaPhase 2

Completed

Idiopathic Pulmonary FibrosisPhase 2

Completed

Showing 10 of 177 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Zofran

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT05581030

Phase 1Active, not recruiting

Multiple Myeloma

NCT03352765

Phase 3Recruiting

Hemolytic Anemia

NCT05057468

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT04872790

Q2 2027

Phase 1Recruiting

Newly Diagnosed

NCT06475235

Phase 2Active, not recruiting

Mantle Cell Lymphoma

NCT02427620

Clinical

Trials by Indication[1]

Lymphoma56 trials

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Completed·UUniversity of California, San Francisco·N/A·NCT00416819·10 enrolled

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01729806·32 enrolled

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00267865·12 enrolled

Show 53 more trials

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00141700·30 enrolled

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Terminated·UUniversity of Miami·Phase 2·NCT01964755·6 enrolled

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00667329·14 enrolled

Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT02501473·52 enrolled

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003204·515 enrolled

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Terminated· Novartis logo

Novartis·Phase 3·NCT01200589·438 enrolled

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01145495·66 enrolled

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Completed·SSymBio Pharmaceuticals·Phase 1·NCT00794638·9 enrolled

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Terminated·—·Phase 2·NCT00110149·12 enrolled

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00809341·27 enrolled

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Completed·CCTI BioPharma·Phase 1·NCT00060684·30 enrolled

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00460109·24 enrolled

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00109967·71 enrolled

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00238368·59 enrolled

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Completed·WWeill Medical College of Cornell University·Phase 1·NCT03036904·31 enrolled

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Unknown status·JJoseph Tuscano·Phase 2·NCT01811368·20 enrolled

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00556699·22 enrolled

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated·UUniversity of Virginia·Phase 2·NCT00265928·46 enrolled

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT01421667·176 enrolled

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00055640·9 enrolled

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05798156·125 enrolled

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00987493·49 enrolled

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·AArtiva Biotherapeutics, Inc.·Phase 1/2·NCT04673617·45 enrolled

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00238238·97 enrolled

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Recruiting· Gilead logo

Gilead·Phase 3·NCT05605899·300 enrolled

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT01992653·85 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00005631

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Withdrawn·MMayo Clinic·Phase 1/2·NCT02281279

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Completed· Roche logo

Roche·Phase 2·NCT02187861·163 enrolled

Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma

Completed·NNational University Hospital, Singapore·N/A·NCT01482754·30 enrolled

A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 2·NCT01392716·48 enrolled

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Completed· Roche logo

Roche·Phase 1·NCT03467373·111 enrolled

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Completed·JJames Rubenstein·Phase 1·NCT01542918·14 enrolled

Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma

Unknown status·UUniversity Hospital Freiburg·Phase 2·NCT00989352·56 enrolled

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Completed· Incyte logo

Incyte·Phase 1·NCT03424122·50 enrolled

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Unknown status·WWenqi Jiang·Phase 3·NCT02428751·216 enrolled

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

Completed·UUniversität des Saarlandes·Phase 2/3·NCT03366272·348 enrolled

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Terminated·WWake Forest University Health Sciences·Phase 1·NCT02168907·1 enrolled

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Completed·—·Phase 2·NCT00720876·30 enrolled

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201877·25 enrolled

Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00765245·44 enrolled

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Withdrawn·CCTI BioPharma·Phase 3·NCT00551239

Treatment of Aggressive Localized Lymphoma

Terminated·FFrench Innovative Leukemia Organisation·Phase 3·NCT00841945·334 enrolled

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Unknown status·PPETHEMA Foundation·Phase 2·NCT05049473·100 enrolled

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003595·120 enrolled

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00369681·51 enrolled

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Terminated·UUniversity of Ulm·Phase 2·NCT04268277·22 enrolled

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00003963·14 enrolled

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT07270835·40 enrolled

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01900496·6 enrolled

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Suspended·HHenan Cancer Hospital·Phase 2·NCT04668365·59 enrolled

Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00946023·135 enrolled

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Completed·—·Phase 2·NCT00783367·50 enrolled

Chronic Lymphocytic Leukemia19 trials

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Recruiting·PPaolo Ghia·Phase 2·NCT04758975·55 enrolled

Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT02194374

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01466153·183 enrolled

Show 16 more trials

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Recruiting·—·Phase 1/2·NCT06644183·64 enrolled

Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003248·104 enrolled

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05023980·309 enrolled

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01611090·578 enrolled

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed·UUniversity of California, San Diego·Phase 2·NCT01199575·30 enrolled

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·DDavid Rizzieri·Phase 2·NCT00636155·20 enrolled

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01253460·18 enrolled

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Approved for marketing· Gilead logo

Gilead··NCT02136511

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003658·60 enrolled

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 3·NCT00769522·564 enrolled

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01419795·3 enrolled

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01027000·68 enrolled

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Completed· Roche logo

Roche·Phase 4·NCT01056510·357 enrolled

Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT01625741·6 enrolled

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00759603·60 enrolled

Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia

Completed·UUniversity Hospital, Tours·Phase 3·NCT00645606·542 enrolled

Rheumatoid Arthritis13 trials

Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 2·NCT00074438·465 enrolled

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

Completed· Roche logo

Roche··NCT01592292·90 enrolled

An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01613027·135 enrolled

Show 10 more trials

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00664521·27 enrolled

A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche·Phase 3·NCT00422383·378 enrolled

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

Completed· Roche logo

Roche·Phase 4·NCT00424502·20 enrolled

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

Completed· Roche logo

Roche·Phase 4·NCT00576433·60 enrolled

A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.

Completed· Roche logo

Roche·Phase 4·NCT00502853·10 enrolled

An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis

Completed·—·Phase 2·NCT00555542·10 enrolled

A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00443651·578 enrolled

A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

Completed· Roche logo

Roche·Phase 3·NCT00502840·193 enrolled

A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.

Completed· Roche logo

Roche·Phase 4·NCT00504777·36 enrolled

A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate

Completed· Roche logo

Roche·Phase 3·NCT00578305·185 enrolled

Mantle Cell Lymphoma9 trials

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Recruiting·RRuijin Hospital·Phase 2·NCT06136351·23 enrolled

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05564052·36 enrolled

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00020943·79 enrolled

Show 6 more trials

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Completed· Roche logo

Roche·Phase 2·NCT00472420·48 enrolled

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT05864742·40 enrolled

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Completed·WWashington University School of Medicine·Phase 2·NCT03623373·13 enrolled

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Unknown status·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT02682641·50 enrolled

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Completed·WWashington University School of Medicine·Phase 1·NCT02728531·18 enrolled

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02427620·131 enrolled

Diffuse Large B-Cell Lymphoma9 trials

Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Completed·UUniversity College, London·Phase 2·NCT00971763·62 enrolled

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed·PPharmatech·Phase 2·NCT00831597·61 enrolled

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00242996·44 enrolled

Show 6 more trials

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00851552·9 enrolled

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Terminated· Roche logo

Roche·Phase 3·NCT00486759·787 enrolled

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Completed· Incyte logo

Incyte·Phase 2/3·NCT02763319·453 enrolled

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01925612·87 enrolled

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00121199·73 enrolled

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00499018·399 enrolled

61 more indications

Follicular Lymphoma9 trials

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Recruiting·—·Phase 2·NCT04998669·100 enrolled

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

Completed· Novartis logo

Novartis·Phase 3·NCT01419665·629 enrolled

Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

Completed·EECOG-ACRIN Cancer Research Group··NCT01381705·259 enrolled

Show 6 more trials

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

Completed·—·Phase 2·NCT01234766·39 enrolled

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06284122·790 enrolled

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Not yet recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07187960·228 enrolled

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Terminated· Gilead logo

Gilead·Phase 2·NCT02258529·10 enrolled

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Withdrawn· Incyte logo

Incyte·Phase 3·NCT04796922

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

Completed· Roche logo

Roche·Phase 3·NCT02569996·124 enrolled

Acute Lymphoblastic Leukemia7 trials

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00671658·220 enrolled

Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00327678·1,080 enrolled

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Recruiting·UUniversity of Washington·Phase 2·NCT05453500·30 enrolled

Show 4 more trials

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Completed·—·Phase 2·NCT04224571·208 enrolled

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05581030·7 enrolled

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04872790·20 enrolled

Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00427791·23 enrolled

Leukemia4 trials

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00039130·105 enrolled

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00669877·56 enrolled

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03096782·6 enrolled

Show 1 more trial

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01973387·160 enrolled

Nephrotic Syndrome3 trials

Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome

Unknown status·UUnknown Sponsor·Phase 4·NCT02382575·120 enrolled

Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome

Completed·UUnknown Sponsor·Phase 3·NCT02438982·120 enrolled

Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 3·NCT05734794·80 enrolled

Systemic Lupus Erythematosus3 trials

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

Completed· GSK logo

GSK·Phase 3·NCT03312907·292 enrolled

Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus

Completed·—·Phase 2·NCT00556192·20 enrolled

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Active, not recruiting·AArtiva Biotherapeutics, Inc.·Phase 1·NCT06265220·51 enrolled

Lenalidomide3 trials

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Completed·WWeill Medical College of Cornell University·Phase 2·NCT01125176·15 enrolled

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Completed·MMassachusetts General Hospital·Phase 1·NCT01400685·34 enrolled

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT03863184·37 enrolled

Multiple Sclerosis2 trials

RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS

Unknown status·KKarolinska Institutet·Phase 3·NCT03979456·200 enrolled

COMparison Between All immunoTherapies for Multiple Sclerosis.

Completed·KKarolinska Institutet··NCT03193866·3,526 enrolled

T-cell non-Hodgkin lymphoma2 trials

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04220008

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01701986·64 enrolled

Granulomatosis with Polyangiitis2 trials

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

Terminated·HHospital for Special Surgery, New York·Phase 4·NCT02626845·3 enrolled

Rituximab in Eosinophilic Granulomatosis With Polyangiitis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02807103·107 enrolled

Renal Transplantation2 trials

Safety and Efficacy Study of Rituximab in Renal Transplantation

Completed·KKarolinska University Hospital·Phase 1·NCT00255593·140 enrolled

RituxiMab INDuction in Renal Transplantation

Unknown status·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT01095172·100 enrolled

Relapsed or Refractory2 trials

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00983619·136 enrolled

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

Terminated·UUniversity Hospital Southampton NHS Foundation Trust·Phase 2·NCT03422523·53 enrolled

Macroglobulinemia2 trials

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00004889·8 enrolled

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Terminated·—·Phase 1·NCT01078974·7 enrolled

Efficacy and Safety2 trials

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Completed· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 3·NCT02787239·407 enrolled

Central Nervous System Lymphoma2 trials

A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Terminated· Roche logo

Roche·Phase 2·NCT00517699·5 enrolled

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04129710·120 enrolled

Hematologic Malignancies1 trial

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02960646·11 enrolled

Churg-Strauss syndrome1 trial

Rituxan in Churg Strauss Syndrome With Renal Involvement

Terminated·FFernando Fervenza·Phase 2·NCT00424749·4 enrolled

Frontline1 trial

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00794820·66 enrolled

Treatment1 trial

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Recruiting·RRuijin Hospital·Phase 3·NCT06496308·78 enrolled

Hemolytic Anemia1 trial

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Recruiting·—·Phase 3·NCT05057468·30 enrolled

Stage III1 trial

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Terminated·UUniversity of Miami·N/A·NCT00772668·3 enrolled

Allogeneic Stem Cell Transplantation1 trial

Non-Myeloablative Allogeneic Stem Cell Transplantation

Completed·MM.D. Anderson Cancer Center·N/A·NCT00525876·49 enrolled

B-cell acute lymphoblastic leukemia1 trial

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Erlangen·Phase 2·NCT00324779·79 enrolled

Kidney Transplant1 trial

Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant

Not yet recruiting·IImperial College London··NCT04496037·170 enrolled

AIN1 trial

Primary Rituximab and Maintenance

Completed·LLymphoma Study Association·Phase 3·NCT00140582·1,217 enrolled

Transplantation1 trial

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT05735717·70 enrolled

Observational Study1 trial

Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

Completed· Roche logo

Roche··NCT02654379·1,408 enrolled

Phase II1 trial

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07034508·134 enrolled

Monoclonal Gammopathy1 trial

RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00259974·60 enrolled

Phase II Clinical Trial1 trial

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001805·20 enrolled

Graves disease1 trial

Rituximab in the Treatment of Graves' Disease

Completed·OOdense University Hospital·Phase 1/2·NCT00150111·20 enrolled

Chemotherapy1 trial

Reduced Chemotherapy in Low Risk DLBCL

Unknown status·RRuijin Hospital·Phase 4·NCT02752815·290 enrolled

Advanced Hematologic Malignancies1 trial

FT516 in Subjects With Advanced Hematologic Malignancies

Terminated·FFate Therapeutics·Phase 1·NCT04023071·72 enrolled

DLBCL1 trial

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Completed· Roche logo

Roche·Phase 3·NCT02406092·139 enrolled

Bone Marrow Transplantation1 trial

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Completed· Incyte logo

Incyte·Phase 3·NCT03112603·330 enrolled

Refractory1 trial

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Terminated·MMassachusetts General Hospital·Phase 2·NCT01173679·10 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00824135·34 enrolled

Chronic Graft Versus Host Disease1 trial

Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Unknown status·TThe Korean Society of Hematopoietic Stem Cell Transplantation·Phase 2·NCT00472225·42 enrolled

Breast Cancer1 trial

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Terminated·MMayo Clinic·Phase 1·NCT03432741·17 enrolled

Retinopathy1 trial

Rituximab for Autoimmune Retinopathy

Completed·NNational Eye Institute (NEI)·Phase 1·NCT01086631·5 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Completed·IIstituto Clinico Humanitas·Phase 3·NCT06325943·37 enrolled

B-cell Malignancies1 trial

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01206777·52 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02356159·34 enrolled

Lung Transplantation1 trial

B Cell Induction in Pediatric Lung Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02266888·45 enrolled

HSCT1 trial

Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients

Completed·TTing YANG··NCT07200583·50 enrolled

Pemphigus1 trial

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus

Recruiting·UUniversity Hospital, Rouen·Phase 4·NCT05898308·133 enrolled

Epilepsy1 trial

Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children

Unknown status·—·Phase 4·NCT04542629·140 enrolled

Active, not recruiting·—·Phase 2·NCT05065554·12 enrolled

ITP1 trial

Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

Unknown status·SShandong University·Phase 3·NCT03443570·200 enrolled

Membranous Nephropathy1 trial

Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy

Unknown status·—·N/A·NCT05782933·2 enrolled

Myasthenia Gravis1 trial

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT05868837·40 enrolled

Lymphoid Malignancies1 trial

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00536978·22 enrolled

Pompe Disease1 trial

Immune Modulation Therapy for Pompe Disease

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT02525172·8 enrolled

Newly Diagnosed1 trial

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Recruiting·—·Phase 1·NCT06475235·15 enrolled

Relapsed/Refractory1 trial

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT04494503·123 enrolled

Lymphoplasmacytic Lymphoma1 trial

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07231952·40 enrolled

CLL/SLL1 trial

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Terminated·—·Phase 1·NCT00543114·9 enrolled

Waldenstrom macroglobulinemia1 trial

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01779167·4 enrolled

Multiple Myeloma1 trial

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03352765·28 enrolled

Unspecified3 trials

T&B Depletion Non Malignant

Unknown status·FFranco Locatelli·Phase 2·NCT01810926·130 enrolled

Rituximab and ABVD for Hodgkin's Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504504·85 enrolled

Cellular Therapy With Cord Blood Cells

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00427557·31 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 26, 1997

RITUXAN

BLA BLA103705

Nov 26, 1997

RITUXAN

NDA BLA103705

Nov 26, 1997

Rituxan

BLA 103705

Feb 10, 2006

RITUXAN

NDA BLA103705

Feb 28, 2006

RITUXAN

NDA BLA103705

Sep 29, 2006

RITUXAN

NDA BLA103705

Sep 29, 2006

RITUXAN

NDA BLA103705

Feb 21, 2007

RITUXAN

NDA BLA103705

Aug 22, 2007

RITUXAN

NDA BLA103705

Sep 28, 2007

RITUXAN

NDA BLA103705

Jan 24, 2008

RITUXAN

NDA BLA103705

Jan 25, 2008

RITUXAN

NDA BLA103705

Sep 8, 2008

RITUXAN

NDA BLA103705

Sep 8, 2008

RITUXAN

NDA BLA103705

Sep 22, 2009

RITUXAN

NDA BLA103705

Oct 16, 2009

RITUXAN

NDA BLA103705

Feb 18, 2010

RITUXAN

NDA BLA103705

Feb 18, 2010

RITUXAN

NDA BLA103705

Oct 6, 2010

RITUXAN

NDA BLA103705

Jan 6, 2011

RITUXAN

NDA BLA103705

Jan 28, 2011

RITUXAN

NDA BLA103705

Apr 19, 2011

RITUXAN

NDA BLA103705

Feb 17, 2012

RITUXAN

NDA BLA103705

Apr 13, 2012

RITUXAN

NDA BLA103705

Jul 13, 2012

RITUXAN

NDA BLA103705

Oct 19, 2012

RITUXAN

NDA BLA103705

Oct 19, 2012

RITUXAN

NDA BLA103705

May 9, 2013

RITUXAN

NDA BLA103705

Sep 24, 2013

RITUXAN

NDA BLA103705

Aug 12, 2014

RITUXAN

NDA BLA103705

Jun 22, 2017

RITUXAN HYCELA

NDA BLA761064

Apr 3, 2018

RITUXAN

NDA BLA103705

Jun 7, 2018

RITUXAN

NDA BLA103705

Oct 18, 2018

RITUXAN

NDA BLA103705

Jan 25, 2019

RITUXAN

NDA BLA103705

Sep 27, 2019

RITUXAN

NDA BLA103705

Nov 25, 2019

RITUXAN

NDA BLA103705

Dec 19, 2019

RITUXAN HYCELA

NDA BLA761064

Jan 23, 2020

RITUXAN

NDA BLA103705

Mar 13, 2020

RITUXAN

NDA BLA103705

May 5, 2020

RITUXAN HYCELA

NDA BLA761064

May 5, 2020

RITUXAN HYCELA

NDA BLA761064

Aug 28, 2020

RITUXAN

NDA BLA103705

Jun 10, 2021

RITUXAN HYCELA

NDA BLA761064

Jun 30, 2021

RITUXAN

NDA BLA103705

Dec 2, 2021

RITUXAN

NDA BLA103705

Dec 17, 2021

RITUXAN

NDA BLA103705

Sources

References

[1]
ClinicalTrials.gov — 1845 trial records for Rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Rituxan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Rituximab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA103705). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: B-Lymphocyte Antigen CD20 Binding Agent[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Rituxan

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Lymphoma56 trials

Chronic Lymphocytic Leukemia19 trials

Rheumatoid Arthritis13 trials

Mantle Cell Lymphoma9 trials

Diffuse Large B-Cell Lymphoma9 trials

Follicular Lymphoma9 trials

Acute Lymphoblastic Leukemia7 trials

Leukemia4 trials

Nephrotic Syndrome3 trials

Systemic Lupus Erythematosus3 trials

Lenalidomide3 trials

Multiple Sclerosis2 trials

T-cell non-Hodgkin lymphoma2 trials

Granulomatosis with Polyangiitis2 trials

Renal Transplantation2 trials

Relapsed or Refractory2 trials

Macroglobulinemia2 trials

Efficacy and Safety2 trials

Central Nervous System Lymphoma2 trials

Hematologic Malignancies1 trial

Churg-Strauss syndrome1 trial

Frontline1 trial

Treatment1 trial

Hemolytic Anemia1 trial

Stage III1 trial

Allogeneic Stem Cell Transplantation1 trial

B-cell acute lymphoblastic leukemia1 trial

Kidney Transplant1 trial

AIN1 trial

Transplantation1 trial

Observational Study1 trial

Phase II1 trial

Monoclonal Gammopathy1 trial

Phase II Clinical Trial1 trial

Graves disease1 trial

Chemotherapy1 trial

Advanced Hematologic Malignancies1 trial

DLBCL1 trial

Bone Marrow Transplantation1 trial

Refractory1 trial

Hematopoietic Stem Cell Transplantation1 trial

Chronic Graft Versus Host Disease1 trial

Breast Cancer1 trial

Retinopathy1 trial

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

B-cell Malignancies1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Lung Transplantation1 trial

HSCT1 trial

Pemphigus1 trial

Epilepsy1 trial

MALT lymphoma1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Neuropathy1 trial

ITP1 trial

Membranous Nephropathy1 trial

Myasthenia Gravis1 trial

Lymphoid Malignancies1 trial

Pompe Disease1 trial

Newly Diagnosed1 trial

Relapsed/Refractory1 trial

Lymphoplasmacytic Lymphoma1 trial

CLL/SLL1 trial

Waldenstrom macroglobulinemia1 trial

Multiple Myeloma1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News